Side by side

1. 1.Binds GHRH receptors on the pituitary, triggering growth-hormone release.
2. 2.Four substitutions slow enzymatic breakdown, so one dose produces a single clear GH pulse rather than a sustained rise.
3. 3.A short pulse is closer to the body's natural rhythm than the week-long elevation produced by the DAC form.
4. 4.Often studied alongside a ghrelin-receptor secretagogue such as ipamorelin, because the two act at different points of the same axis.
5. 5.Raises IGF-1 secondarily; that is the marker trials measure.

• Growth-hormone secretion research in healthy adults
• Body-composition and recovery claims, which have not been tested in trials
• Combination with ipamorelin in laboratory work on GH pulsatility
• Testing of growth-hormone reserve

• A measurable growth-hormone pulse within 15–30 minutes
• Modest IGF-1 increase with repeated use
• Reported better sleep and recovery, based on user accounts rather than trials
• Fluid retention and joint stiffness, as with the growth-hormone class

• Headache, flushing and dizziness shortly after dosing
• Water retention and joint aches
• Numbness or tingling in the hands
• Potential consequences of raised IGF-1 with long-term use

Research context only — no approved human protocol exists. Human studies used single microgram-per-kilogram doses to characterise GH pulses. Vendor schedules, commonly 100–300 micrograms once or twice daily, sometimes with 200 micrograms of ipamorelin, are community practice rather than clinical evidence.

Research context only